AIMS/HYPOTHESIS: Post-translational modifications, such as isomerisation of native proteins, may create new antigenic epitopes and play a role in the development of the autoimmune response. Protein-L-isoaspartate (D-aspartate) O-methyltransferase (PIMT), encoded by the gene PCMT1, is an enzyme that recognises and repairs isomerised Asn and Asp residues in proteins. The aim of this study was to assess the role of PIMT in the development of type 1 diabetes. MATERIALS AND METHODS: Immunohistochemical analysis of 59 normal human tissues was performed with a monoclonal PIMT antibody. CGP3466B, which induces expression of Pcmt1, was tested on MIN6 and INS1 cells, to assess its effect on Pcmt1 mRNA and PIMT levels (RT-PCR and western blot) and apoptosis. Forty-five diabetes-prone BioBreeding (BB) Ottawa Karlsburg (OK) rats were randomised to receive 0, 14 or 500 microg/kg (denoted as the control, low-dose and high-dose group, respectively) of CGP3466B from week 5 to week 20. RESULTS: A high level of PIMT protein was detected in beta cells. CGP3466B induced a two- to threefold increase in Pcmt1 mRNA levels and reduced apoptosis by 10% in MIN6 cells. No significant effect was seen on cytokine-induced apoptosis or PIMT protein levels in INS1 cells. The onset of diabetes in the BB/OK rats was significantly delayed (85.6+/-9.0 vs 84.3+/-6.8 vs 106.6+/-13.5 days, respectively; p<0.01 for high-dose vs low-dose and control groups), the severity of the disease was reduced (glucose 22.2+/-3.2 vs 16.9+/-2.6 vs 15.8+/-2.7 mmol; p<0.01 for high- and low-dose groups vs control group) and residual beta cells were more frequently identified (43% vs 71% vs 86%; p<0.05 for high-dose vs control group) in the treated animals. CONCLUSIONS/ INTERPRETATION: The results support a role for post-translational modifications and PIMT in the development of type 1 diabetes in the diabetes-prone BB rat, and perhaps also in humans.
AIMS/HYPOTHESIS: Post-translational modifications, such as isomerisation of native proteins, may create new antigenic epitopes and play a role in the development of the autoimmune response. Protein-L-isoaspartate (D-aspartate) O-methyltransferase (PIMT), encoded by the gene PCMT1, is an enzyme that recognises and repairs isomerised Asn and Asp residues in proteins. The aim of this study was to assess the role of PIMT in the development of type 1 diabetes. MATERIALS AND METHODS: Immunohistochemical analysis of 59 normal human tissues was performed with a monoclonal PIMT antibody. CGP3466B, which induces expression of Pcmt1, was tested on MIN6 and INS1 cells, to assess its effect on Pcmt1 mRNA and PIMT levels (RT-PCR and western blot) and apoptosis. Forty-five diabetes-prone BioBreeding (BB) Ottawa Karlsburg (OK) rats were randomised to receive 0, 14 or 500 microg/kg (denoted as the control, low-dose and high-dose group, respectively) of CGP3466B from week 5 to week 20. RESULTS: A high level of PIMT protein was detected in beta cells. CGP3466B induced a two- to threefold increase in Pcmt1 mRNA levels and reduced apoptosis by 10% in MIN6 cells. No significant effect was seen on cytokine-induced apoptosis or PIMT protein levels in INS1 cells. The onset of diabetes in the BB/OK rats was significantly delayed (85.6+/-9.0 vs 84.3+/-6.8 vs 106.6+/-13.5 days, respectively; p<0.01 for high-dose vs low-dose and control groups), the severity of the disease was reduced (glucose 22.2+/-3.2 vs 16.9+/-2.6 vs 15.8+/-2.7 mmol; p<0.01 for high- and low-dose groups vs control group) and residual beta cells were more frequently identified (43% vs 71% vs 86%; p<0.05 for high-dose vs control group) in the treated animals. CONCLUSIONS/ INTERPRETATION: The results support a role for post-translational modifications and PIMT in the development of type 1 diabetes in the diabetes-prone BBrat, and perhaps also in humans.
Authors: E Kragten; I Lalande; K Zimmermann; S Roggo; P Schindler; D Muller; J van Oostrum; P Waldmeier; P Furst Journal: J Biol Chem Date: 1998-03-06 Impact factor: 5.157
Authors: T A M A Al-Bukhari; P M Radford; G Bouras; C Davenport; S M Trigwell; G-F Bottazzo; M Lai; H L Schwartz; P J Tighe; I Todd Journal: Clin Exp Immunol Date: 2002-10 Impact factor: 4.330
Authors: K Nielsen; M Kruhøffer; T Orntoft; T Sparre; H Wang; C Wollheim; M C Jørgensen; J Nerup; A E Karlsen Journal: Diabetologia Date: 2004-12-17 Impact factor: 10.122
Authors: J Nerup; T Mandrup-Poulsen; S Helqvist; H U Andersen; F Pociot; J I Reimers; B G Cuartero; A E Karlsen; U Bjerre; T Lorenzen Journal: Diabetologia Date: 1994-09 Impact factor: 10.122
Authors: Stuart I Mannering; Leonard C Harrison; Nicholas A Williamson; Jessica S Morris; Daniel J Thearle; Kent P Jensen; Thomas W H Kay; Jamie Rossjohn; Ben A Falk; Gerald T Nepom; Anthony W Purcell Journal: J Exp Med Date: 2005-10-31 Impact factor: 14.307
Authors: Mei-Ling Yang; Hester A Doyle; Steven G Clarke; Kevan C Herold; Mark J Mamula Journal: Antioxid Redox Signal Date: 2017-12-11 Impact factor: 8.401
Authors: Noemí Alejandra Saavedra-Ávila; Upasana Sengupta; Begoña Sánchez; Ester Sala; Laura Haba; Thomas Stratmann; Joan Verdaguer; Dídac Mauricio; Belén Mezquita; Ana Belén Ropero; Ángel Nadal; Conchi Mora Journal: Proc Natl Acad Sci U S A Date: 2014-08-04 Impact factor: 11.205
Authors: Ester Sala; Celia Vived; Júlia Luna; Noemí Alejandra Saavedra-Ávila; Upasana Sengupta; A Raúl Castaño; Sabrina Villar-Pazos; Laura Haba; Joan Verdaguer; Ana B Ropero; Thomas Stratmann; Javier Pizarro; Manuel Vázquez-Carrera; Angel Nadal; Jill M Lahti; Conchi Mora Journal: Front Immunol Date: 2021-02-10 Impact factor: 7.561